MedTrace Logo

Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy

NCT01263444 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2014-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.

Conditions

Interventions

DRUG

Brinzolamide 1% / timolol 0.5% Fixed Combination

DRUG

Habitual prostaglandin monotherapy

Topical ocular therapy used daily as prescribed

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Severine Durier, Pharm. D · Alcon Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-04-30
Completion
2013-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263444 on ClinicalTrials.gov